Send us Fan Mail

Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around drug development.

The conversation addressed the various ways that the challenges that the COVID-19 pandemic created for clinical trials in 2020 played out in the drug development presentations at #ILC2021: a higher level of retrospective analysis of earlier trials and relatively few pieces of novel Phase 2b or Phase 3 research adding to knowledge and insight. The group noted that cirrhosis received relatively more attention and even some fresh data as with the efruxifermin late-breaker publication. Finally, the group discussed some of the studies and insights we can expect to see between now and 2022.